SAI LIFE SCIENCES LTD (SAILIFE) Fair Value & Analysis
Healthcare · IN · Market cap ₹267B (≈ $2.8B)
What is SAI LIFE SCIENCES LTD really worth?
Below-average quality, and trading another 338% above our fair value of ₹361.59.
Strengths
Risks
Fair value as of: Aug 13, 2026
From 14 valuation models · updated 22 days ago
Fair value updated Aug 13, 2026, revised from ₹328.72 to ₹361.59 (+10.0%) since Aug 8, 2026. Share price +13.6% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (₹451.99). The favourable scenario is already priced in.
- Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (21 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
21‑month range ₹640.25 – ₹1,587 · fair‑value band ₹270.50 – ₹451.99 · the ₹1,584 price screens above the ₹361.59 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
SAI LIFE SCIENCES LTD (SAILIFE) currently trades at ₹1,584, while our model-based Fair Value estimate is ₹361.59, implying the stock looks roughly 338.2% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of ₹516.55 per share, and 0 of the 14 models we run sit above the ₹1,584 price. Bear case: the Asset-Based group reads lowest at ₹78.39, and 14 of the 14 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, SAI LIFE SCIENCES LTD generated revenue of ₹21.9B at a net margin of 15.9%. Revenue grew 3.9% year over year. It earns a return on equity of 15.1%. Net debt stands at ₹1.8B. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹270.50 (bear case) to ₹451.99 (bull case); at ₹1,584, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 104% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −54% fair-value upside, at −77%, SAILIFE screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2026 figures, and about 5 months have passed since. In that time the company retained roughly ₹7.13 per share, which is 2.0 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 14 models by family
Widest divergence: Growth Earnings (₹516.55) versus Asset-Based (₹78.39). Highest evidence: EPV (74).
Notify me when SAILIFE reaches fair value
Put SAILIFE on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 50 · Market factors (momentum, volatility) 86
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services.
Full company description
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
SAI LIFE SCIENCES LTD reported revenue of ₹21.9B in FY2026 versus ₹8.7B in FY2022, a compound +26.0%/yr. Reported net income was ₹3.5B in FY2026, compounding +173.6%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
SAILIFE screens 338% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 130 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $630.70 | $308.19 | −51% |
| Danaher Corporation DHR | $215.68 | $103.88 | −52% |
| WuXi AppTec Co 2359 | HK$189.30 | HK$150.16 | −21% |
| Lonza Group LONN | CHF 576.60 | CHF 259.80 | −55% |
| IDEXX Laboratories, Inc IDXX | $556.69 | $255.77 | −54% |
| Agilent Technologies, Inc A | $149.93 | $61.53 | −59% |
| Waters Corporation WAT | $416.15 | $121.96 | −71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | −44% |
| Illumina, Inc ILMN | $215.59 | $95.51 | −56% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | −57% |
Compare SAI LIFE SCIENCES LTD with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is SAI LIFE SCIENCES LTD (SAILIFE) overvalued or undervalued?
What is the fair value of SAILIFE?
What is the quality score of SAILIFE?
What is the revenue of SAI LIFE SCIENCES LTD (SAILIFE)?
What is the net profit margin of SAILIFE?
Watch SAI LIFE SCIENCES LTD in the live analysis
One click puts SAI LIFE SCIENCES LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.